Holen Sie sich die Stockscreener-App
4.10
9.89%
-0.45
Handel nachbörslich:
4.09
-0.010
-0.24%
Schlusskurs vom Vortag:
$4.55
Offen:
$4.53
24-Stunden-Volumen:
104.98K
Relative Volume:
0.47
Marktkapitalisierung:
$144.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-2.0724
EPS:
-1.9784
Netto-Cashflow:
-
1W Leistung:
+1.74%
1M Leistung:
+58.91%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.07
$4.5775
1-Wochen-Bereich:
$3.92
$4.75
52-Wochen-Spanne:
$2.34
$8.79
Anteris Technologies Global Corp Stock (AVR) Company Profile
Firmenname
Anteris Technologies Global Corp
Sektor
Telefon
651-493-0606
Adresse
860 BLUE GENTIAN ROAD, EAGAN
Vergleichen Sie AVR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
4.10 | 144.84M | 0 | 0 | 0 | -1.9784 |
|
ISRG
Intuitive Surgical Inc
|
565.94 | 192.17B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
171.02 | 47.90B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.24 | 47.53B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
246.99 | 35.88B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
80.47 | 16.25B | 3.93B | 415.40M | 384.70M | 2.06 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-08 | Eingeleitet | Lake Street | Buy |
| 2025-01-07 | Eingeleitet | Barclays | Overweight |
| 2025-01-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
Anteris Technologies Global Corp Aktie (AVR) Neueste Nachrichten
Anteris Technologies advances toward PARADIGM trial after key regulatory and clinical milestones - Proactive financial news
Anteris scales for pivotal PARADIGM Trial, plunging R&D investment into clinical activities - Proactive financial news
The morning catch up: ASX to extend gains as global optimism lifts markets - Proactive financial news
Anteris Technologies Advances Clinical Trial Efforts with DurAVR® THV - TipRanks
Anteris Technologies Reports Q1 2025 Results and Strategic Fund Allocation - TipRanks
Anteris Announces Results for the First Quarter of 2025 - The Manila Times
Anteris Technologies Files Amendment to Annual Report - TipRanks
Anteris Technologies Announces Cessation of Certain Securities - TipRanks
Anteris Technologies Global Corp. (AVR) Receives a Buy from Lake Street - The Globe and Mail
ASX Runners of the Week: Redstone Resources, Anteris & Jindalee Lithium - businessnews.com.au
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target - Investing.com
Anteris Technologies Announces Cessation of Securities - TipRanks
Anteris Technologies Announces New Securities Quotation - TipRanks
NanoVibronix (NASDAQ:NAOV) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Review - Defense World
Anteris Technologies Reports March 2025 CDI Adjustments - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV By Investing.com - Investing.com Canada
Anteris reports over 100 patients treated with new heart valve By Investing.com - Investing.com South Africa
Anteris Technologies Hits Milestone with DurAVR® Heart Valve Treatment - Zenopa
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewswire
Anteris reports over 100 patients treated with new heart valve - Investing.com
Anteris Technologies announces 100 patients treated with DurAVR THV - TipRanks
Anteris Technologies Achieves Key Milestone in Cardiac Care - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV - Investing.com
Anteris Technologies Achieves Milestone with DurAVR® Heart Valve - TipRanks
Anteris Technologies marks clinical milestone with more than 100 patients treated using flagship DurAVR® THV - Proactive financial news
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq - MSN
Head to Head Survey: Anteris Technologies Global (NASDAQ:AVR) & United Health Products (OTCMKTS:UEEC) - Defense World
Anteris Technologies reports one-year patient outcomes for DurAVR THV - TipRanks
Anteris shares rise on positive valve trial results By Investing.com - Investing.com Canada
Anteris Reports One-Year Patient Outcomes for DurAVR® THV - The Manila Times
Anteris shares rise on positive valve trial results - Investing.com India
Anteris Technologies Unveils Positive DurAVR® Patient Outcomes - TipRanks
Anteris Technologies delivers strong one-year results for DurAVR® Transcatheter Heart Valve - Proactive financial news
Analyzing Anteris Technologies Global (NASDAQ:AVR) & CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Anteris Technologies Global (NASDAQ:AVR) Stock Price Down 6.2% – What’s Next? - Defense World
Anteris Technologies: Advancing Toward FDA Approval with Positive Buy Rating - TipRanks
Anteris Technologies reports annual financial results By Investing.com - Investing.com South Africa
Anteris Technologies reports annual financial results - Investing.com India
Anteris Technologies 2024 financials strong following Nasdaq debut, with plans for heart valve pivotal trial this year - Proactive financial news
Anteris Technologies: A Trailblazing Year of Innovation and Expansion - Kondor EXP
The morning catch up: ASX to reverse losses despite war of words over tariffs - Proactive financial news
Finanzdaten der Anteris Technologies Global Corp-Aktie (AVR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):